MC
STRO icon

Merck & Co’s Sutro Biopharma STRO Stock Holding History

Merck & Co’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.78M Hold
272,351
– – 1.94% 8
2025
Q4 		$3.15M Hold
272,351
– – 1.14% 7
2025
Q3 		$2.37M Hold
272,351
– – 1.04% 7
2025
Q2 		$1.94M Hold
272,351
– – 0.9% 7
2025
Q1 		$1.77M Hold
272,351
– – 1.08% 7
2024
Q4 		$5.01M Buy
+272,351
New +$8.31M 1.94% 6

Other funds holding STRO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Merck & Co's STRO Position: Q1 2026 in Review

Merck & Co held its Sutro Biopharma (STRO) position steady in Q1 2026 at 272,351 shares worth $6.78M. The position accounts for 1.94% of the portfolio, ranked #8.

Merck & Co first reported a position in STRO in Q4 2024 and has held it in 6 quarters since. 78 funds tracked by Wall St. Rank hold STRO as of Q1 2026.

  • Merck & Co held 272,351 shares of Sutro Biopharma worth $6.78M as of Q1 2026.
  • Merck & Co left its Sutro Biopharma share count unchanged in Q1 2026.
  • Sutro Biopharma made up 1.94% of Merck & Co's portfolio in Q1 2026, its #8 holding.
  • Merck & Co first reported a position in Sutro Biopharma in Q4 2024 and has held it in 6 quarters since.
  • 78 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2026.

Based on Merck & Co's 13F filing for Q1 2026, filed 13 May 2026.